Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective clinical trial of disulfiram plus copper in men with metastatic castration‐resistant prostate cancer
Authors
Keywords
-
Journal
PROSTATE
Volume 82, Issue 7, Pages 858-866
Publisher
Wiley
Online
2022-03-15
DOI
10.1002/pros.24329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer
- (2020) Subha Bakthavatsalam et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
- (2019) Jiayi Huang et al. JOURNAL OF NEURO-ONCOLOGY
- Highly Stable, Coordinated Polymeric Nanoparticles Loading Copper(II) Diethyldithiocarbamate for Combinational Chemo/Chemodynamic Therapy of Cancer
- (2019) Xinyu Peng et al. BIOMACROMOLECULES
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Leveraging gamma-glutamyl transferase to direct cytotoxicity of copper dithiocarbamates against prostate cancer cells
- (2018) Subha Bakthavatsalam et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers
- (2018) Wu Chen et al. ACS Applied Materials & Interfaces
- Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram
- (2018) Dusana Majera et al. PROSTATE
- Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent
- (2017) Mohamed Wehbe et al. International Journal of Nanomedicine
- 64CuCl2PET/CT in Prostate Cancer Relapse
- (2017) Arnoldo Piccardo et al. JOURNAL OF NUCLEAR MEDICINE
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Role of 64CuCl2 PET/CT in staging of prostate cancer
- (2015) Enza Capasso et al. ANNALS OF NUCLEAR MEDICINE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Copper Signaling Axis as a Target for Prostate Cancer Therapeutics
- (2014) R. Safi et al. CANCER RESEARCH
- Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer
- (2013) M T Schweizer et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth
- (2010) Jianqing Lin et al. PROSTATE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started